ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear
ResMed to Report First Quarter Fiscal 2025 Earnings on October 24, 2024
Zacks.com Featured Highlights Ferrari, Vertex, ResMed and Hubbel
ResMed Stock Is Surging. Expect More Gains for the Medical Equipment Maker. -- Barrons.com
Resmed Inc Reports CDI Fluctuations in September
ResMed (RMD) Upgraded to Buy: What Does It Mean for the Stock?
Bristol-Myers Tops Growth Chart Among S&P 500 Healthcare Stocks in Q3
A Quick Look at Today's Ratings for ResMed(RMD.US), With a Forecast Between $280 to $280
ResMed Is Maintained at Sector Perform by RBC Capital
Bank of America Securities Sticks to Its Buy Rating for Resmed (RMD)
Needham Maintains ResMed(RMD.US) With Hold Rating
Needham Reaffirms Their Hold Rating on Resmed (RMD)
Needham Reiterates Hold on ResMed
ResMed Unveils 2030 Strategy To Drive Growth, Profitability, And Shareholder Returns; New 5-Year Outlook Includes High-Single-Digit Revenue Growth; Earnings Growth Higher Than Revenue Growth
Express News | Resmed: New Five-Year Financial Outlook Includes High-Single-Digit Revenue Growth
ResMed Unveils 2030 Strategy to Drive Growth, Profitability, and Shareholder Returns
Express News | Resmed Unveils 2030 Strategy to Drive Growth, Profitability, and Shareholder Returns
Mizuho Securities Maintains ResMed(RMD.US) With Buy Rating, Raises Target Price to $250
ResMed Enhances CPAP Therapy With Its First Fabric Mask, Designed To Make It Easier For People To Embrace Their Treatment And Improve Overall Sleep Health
ResMed Unveils New Collection of Digital and Personalized Solutions Designed to Improve Sleep Health